in 32%, T2c in 16% and T3 in 2% of patients.
|
|
- Mae Hawkins
- 6 years ago
- Views:
Transcription
1 BJUI Gleason 7 prostate cancer treated with lowdose-rate brachytherapy: lack of impact of primary Gleason pattern on biochemical failure Richard G. Stock, Joshua Berkowitz, Seth R. Blacksburg and Nelson N. Stone * Departments of Radiation Oncology and * Urology, Mount Sinai School of Medicine, New York, NY, USA Accepted for publication 2 December 211 Study Type Prognosis (case series) Level of Evidence 4 OBJECTIVES To report the biochemical outcomes for Gleason 7 prostate cancer treated with brachytherapy. To analyse the impact of the primary Gleason pattern as well as other diseaseand treatment-related factors on outcome. PATIENTS AND METHODS A total of 56 patients with Gleason 7 prostate cancer were treated between 199 and 28 with brachytherapy, alone or in combination with hormonal therapy and/or external beam radiation therapy. There were 352 patients with Gleason pattern and 28 with Gleason pattern The mean (range) presenting PSA level was 11.2 (1 3) ng/ml, and the median was 7.8 ng/ml. The presenting clinical stages were T1b in 1%, T1c in 33%, T2a in 16%, T2b What s known on the subject? and What does the study add? There appears to be a clear difference in cancer control outcomes for patients with Gleason scores of and those with scores of after radical prostatectomy. It has been documented that patients with Gleason prostate cancer have higher incidences of non-organ-confined disease than those with primary pattern 3. Higher rates of extracapsular extension, seminal vesicle invasion and positive margins have been found to be associated with primary pattern 4 over 3. These higher rates of non-organ-confined disease can lead to increased biochemical failure, which, in turn, can lead to higher mortality rates. This study provides information on the prognostic significance of primary Gleason pattern in the brachytherapy management of prostate cancer. in 32%, T2c in 16% and T3 in 2% of patients. RESULTS The actuarial freedom from biochemical failure rate at 1 years was 82%. There was no significant difference between 1-year freedom from biochemical failure rates for patients with Gleason scores of (79%) and those with scores of 4 +3 (82%). Biologically effective dose and presenting PSA level were both significant predictors of biochemical failure in multivariate analysis. CONCLUSIONS The primary Gleason pattern in Gleason 7 prostate cancer shows no significant effect on biochemical failure when treated with brachytherapy. These results are different from those found after radical prostatectomy and are probably attributable to the enhanced local control afforded by a brachytherapy approach to this disease subset. KEYWORDS prostate cancer, Gleason score 7, primary Gleason grade, brachytherapy INTRODUCTION Gleason 7 prostate cancer found on prostate biopsy is used in the National Comprehensive Cancer Network (NCCN) risk group stratification ( org ) to denote intermediate-risk prostate cancer. This grade of cancer can behave more like low-risk disease in certain patients or more aggressively in others. The number of cores involved, as well as other presenting disease characteristics, e.g. stage and presenting PSA level, can influence the natural history of Gleason 7 disease. Depending on the primary pattern, it can be read by a pathologist as either Gleason or The primary Gleason pattern has been found to be highly prognostic after radical prostatectomy. Most radical prostatectomy reports have found a primary pattern of 4 to be a significant predictor of biochemical failure and mortality [1 6 ]. Different treatment approaches have been recommended for this group of patients with prostate cancer. Radical prostatectomy continues to be the most popular treatment for Gleason 7 disease [1 6 ]. From a radiation approach, various treatments have been used. A Gleason score of 7 has been considered an adverse feature and, historically, patients were selected for trials testing the use of adjuvant hormonal therapy with external beam radiation therapy (EBRT) [7 ]. Brachytherapy alone or in combination with hormonal therapy and/or EBRT have all been used to treat Gleason 7 prostate cancer [8 ] , doi:1.1111/j x x 1257
2 STOCK ET AL. The present study examines the biochemical outcomes for Gleason 7 prostate cancer treated with low-dose-rate brachytherapy. The prognostic importance of the primary Gleason pattern and other disease- and treatment-related factors, with regard to biochemical failure, were analysed. The purpose was to determine the relative importance of primary Gleason pattern in the brachytherapy management of Gleason 7 prostate cancer as well as to identify unique features that portend a worse prognosis. PATIENTS AND METHODS A total of 56 patients with Gleason score 7 adenocarcinoma on prostate biopsy were treated with brachytherapy between 199 and 28 at Mount Sinai Hospital in New York. These patients had a minimum of 2 years follow-up. All pathology was reviewed by a single pathologist. There were 352 patients with Gleason pattern and 28 with Gleason pattern The number of cores and percentage involvement by core were not available on a consistent basis and, therefore, were not analysed. The mean (range) presenting PSA level was 11.2 (1 3) ng/ml with a median of 7.8 ng/ml. The presenting clinical stages were T1b in 1%, T1c in 33%, T2a in 16%, T2b in 32%, T2c in 16% and T3 in 2% of patients. Using the NCCN risk group stratification, there were 429 patients in the intermediate-risk and 131 in the high-risk group. Treatment included four main groups: implant alone (palladium [pd ]-13 or iodine [ I ] -125; 24 patients), implant plus neoadjuvant (3 months) and adjuvant hormonal therapy (3 months; 89 patients), implant (pd-13 or I-125) plus EBRT ( Gy; median: 59.4 Gy; 79 patients) and 9 months of hormonal therapy in addition to combined implant and EBRT (368 patients). At our institution, the treatment approach for patients with intermediate disease has changed over time from treatment with implant alone in the early years to a more combined approach with hormonal therapy or brachytherapy in the latter years of the study period [8 ]. The primary Gleason pattern was never considered a criterion for selecting a particular treatment regimen. All implants were performed using a real-time ultrasonography-guided system, which has been described previously [9 ]. Pd-13 was used in 544 patients and I-125 in 16 patients. One month after seed implant, CT-based dosimetry was performed. The implant dose was calculated using the dose-volume histogram parameter of D9. Biologically effective dose (BED) values were calculated for all treatments. The formula used has been reported previously [1 ]. The median (range) BED for all treatments was 22 (91 278) Gy2. All patients were followed up by PSA assessment and DREs every 6 months. The median (range) follow-up was 65 (24 2) months. Biochemical failure was defined using the Phoenix definition [11 ]. Actuarial survival curves were calculated using Kaplan Meier analysis. Comparisons between survival curves were calculated using the log-rank test. Multivariate analysis of survival was performed using Cox regression [12 ]. A P value of <5 was considered to indicate statistical significance. RESULTS There were a total of 55 PSA failures detected over the follow-up period (a 9.8% crude failure rate). The actuarial freedom from biochemical failure (FFBF) at 1 years was 82% ( Fig. 1 ). The effect of disease- and treatment-related factors on biochemical failure is shown in Table 1. Using univariate analysis, there was no significant difference between patients with Gleason scores of (79%) and those with scores of 4 +3 (82% [Fig. 2 ] ). BED was a significant predictor of PSA failure. Both thresholds of 16Gy 2 and 18Gy 2 yielded significant results, although the smallest P value was found using a dose threshold of 16 Gy 2. ( Fig. 3 ). This threshold also yielded a significant result in Cox regression ( Table 2 ). The most significant predictor in both univariate and multivariate analysis was PSA level. There was little difference between groups of 1 ng/ml and >1 2 ng/ml, but patients with PSA levels >2 ng/ml had significantly worse outcomes, with a 1-year FFBF rate of 54% (Fig. 4 ). In univariate analysis, treatment with implant alone yielded significantly worse outcomes than were found in the other treatment groups but effect was nonsignificant in multivariate analysis. In addition, NCCN risk group was a significant predictor (favouring FIG. 1. Overall freedom from biochemical failure. 2 years No.@ risk intermediate- over high-risk) in univariate but not in Cox regression analysis. DISCUSSION There has been much discussion in the urological literature on the relative importance of the primary Gleason pattern in Gleason score 7 prostate cancer. The vast majority of reports on outcomes after radical prostatectomy show inferior biochemical control for patients with Gleason score 7 with primary pattern 4 vs primary pattern 3 (Table 3 [1 6 ] ). Various explanations have been given to explain these findings. The original hypothesis was that patients with primary pattern 4 did worse than those with pattern 3 because they had biologically more aggressive disease and were more likely to harbour microscopic systemic disease [3 ]. This conclusion worked well in explaining the differences seen in progression-free survival between the primary patterns after radical prostatectomy. The theory of microscopic spread is supported by a study by Stark et al. [13 ] which analysed radical prostatectomy outcomes from patients in two prospective studies, the Physicians Health study and the Health Professional follow-up study. The results of their analysis found a threefold increase in mortality for patients treated with radical prostatectomy with Gleason score 4 +3 vs those with (HR 2.4; 95% CI, 1. to 5.6). The data from the present study, as well as those from the study by Merrick et al. [14 ], which also examines this issue in patients
3 GLEASON 7 PROSTATE CANCER TABLE 1 Effect of disease- and treatment-related factors on FFBF rates Factor No. of patients No. of failures 1-year FFBF, % P Gleason score (primary + secondary pattern) NCCN risk group Intermediate High PSA, ng/ml > > <1 Stage t2a t2b Treatment Implant alone Implant + EBRT Implant + HRM Trimodality Supplemental EBRT No Yes Adjuvant hormonal therapy No Yes BED 16 Gy >16 Gy <18 Gy >18 Gy FIG. 2. Effect of primary Gleason grade. Percent Free From PSA Failure 2 1 Effect of Primary Gleason Grade P = FIG. 3. Effect of BED on biochemical failure. 2 1 Effect of Biologically Effective dose P = >16 Gy2 16 Gy2 FIG. 4. Effect of initial PSA on biochemical failure. TABLE 2 Cox regression analysis of biochemical failure 95% CI for Exp(B) Factor P Exp(B) Lower Upper Risk group Treatment groups Hormonal treatment PSA groups ( 1, >1 2, >2 ng/ml) Stage ( T2a, T2b) BED ( 16, >16 Gy2 ) Effect of initial PSA PSA 1 ng/ml PSA > 1 2 ng/ml PSA > 2 ng/ml 2 1 P < Exp(B), exponential (B). undergoing brachytherapy, suggest a different theory to explain the results from the radical prostatectomy studies: patients with primary pattern 4 have a higher local failure rate than those with primary pattern 3. It has been documented that patients with Gleason prostate cancer have higher incidences of non-organ-confined disease than those with primary pattern 3. Higher rates of extracapsular extension, seminal vesicle invasion and positive margins have been correlated with primary pattern 4 over 3. These higher rates of non-organ-confined disease can lead to increased biochemical failure, which, in turn, can lead to higher mortality rates. The idea that disease left behind after radical prostatectomy and margin status are somehow related to the primary pattern has been examined in a study by Brimo et al. [15 ]. In looking at patients with extracapsular extension and positive margins, those authors found that the primary pattern at the positive margin site
4 STOCK ET AL. TABLE 3 Effect of primary Gleason grade on biochemical failure after prostatectomy Study Gleason score No. of patients Reporting year FFBF P Khoddami et al. [1] % % Tollefson et al. [2] % < % Chan et al. [3] % < % Sim et al. [4] % < % Trock et al. [5] % < % Alenda et al. [6] % < % the patient s presentation, including PSA level, clinical stage and volume of cancer on biopsy. In conclusion, we found that the primary Gleason pattern in Gleason 7 prostate cancer had no significant effect on biochemical failure when treated with brachytherapy. These results are different from those found after radical prostatectomy and are probably attributable to the enhanced local control afforded by a brachytherapy approach to this disease subset. CONFLICT OF INTEREST predicted biochemical failure. Those with had only a 12% FFBF rate at 6 years compared with 25% for those with Results from SWOG 8794 [16 ], which tested the efficacy of adjuvant postoperative radiation therapy after radical prostatectomy for high-risk features, found that radiation therapy increased local control and subsequently survival and concluded that the predominant mode of failure of patients in the high-risk group was local [16,17 ]. Brachytherapy results in the highest possible delivered radiation dose and also treats extracapsular disease [1 ]. The results from the present study, as well as those from Merrick et al. [14 ], suggest that brachytherapy, with or without supplemental EBRT, improves local control. This is supported by the high negative posttreatment biopsy results after brachytherapy and brachytherapy plus EBRT [18 ]. This enhanced local control seems to result in similar biochemical control rates between primary pattern 4 vs pattern 3. The poorer biochemical control rates seen with primary pattern 4 after radical prostatectomy are probably attributable to local failure which is not as much of an issue when a brachytherapy approach is used. In the present study, the FFBF at 1 years was 79% for patients and 82% for 4 +3 patients ( P =.66). Similarly, Merrick et al. [14 ] found no difference in biochemical failure at 1 years between patients with and those with The two most significant predictors of biochemical failure were PSA level and BED. A big decrease in the cancer control rate occurred at a PSA level of 2 ng/ml. This supports the NCCN risk group stratification, which places a patient with Gleason 7 disease into a high-risk group as the PSA level increases to > 2 ng/ml. The FFBF rate at 1 years of 54% in patients with PSA > 2 ng/ml suggests that these patients carry a high risk of having microscopic disease in the lymph nodes or occult systemic spread. Better systemic approaches need to be explored in these patients. The BED showed a highly significant effect on biochemical control. This highlights the need for high-quality, high-dose treatment to eradicate Gleason 7 prostate cancer. Although the type of treatment did not significantly affect biochemical failure in multivariate analysis, in univariate analysis, treatment with implant alone resulted in significantly worse biochemical control than with other treatment approaches. We reported a similar finding in a previous publication on patients in the intermediaterisk group [19 ]. This emphasizes the importance of the current Radiation Therapy Oncology Group trial (232), which randomizes patients with intermediate-risk prostate cancer to implant alone vs combined therapy with implant and EBRT ( ). It is hoped that the RTOG trial will help to identify the optimum brachytherapy treatment for patients with intermediate-risk prostate cancer. Currently, we treat patients with Gleason 7 prostate cancer with either combined hormonal therapy and implant or implant and EBRT (with or without hormonal therapy). The exact treatment is individualized based on None declared. REFERENCES 1 Khoddami SM, Shariat SF, Lotan Y et al. Predictive value of primary Gleason pattern 4 in patients with Gleason score 7 tumours treated with radical prostatectomy. BJU Int 24 ; 94 : Tollefson MK, Leibovich BC, Slezak JM, Zincke H, Blute ML. Long-term prognostic significance of primary Gleason pattern in patients with Gleason score 7 prostate cancer: impact on prostate cancer specific survival. J Urol 26 ; 175 : Chan TY, Partin AW, Walsh PC, Epstein JI. Prognostic significance of Gleason score versus Gleason score tumor at radical prostatectomy. Urology 2 ; 56 : Sim HG, Telesca D, Culp SH et al. Tertiary Gleason pattern 5 in Gleason 7 prostate cancer predicts pathological stage and biochemical recurrence. J Urol 28 ; 179 : Trock BJ, Guo CC, Gonzalgo ML, Magheli A, Loeb S, Epstein JI. Tertiary Gleason patterns and biochemical recurrence after prostatectomy: proposal for a modified Gleason scoring system. J Urol 29 ; 182 : Alenda O, Ploussard G, Mouracade P et al. Impact of the primary Gleason pattern on biochemical recurrence-free survival after radical prostatectomy: a single-center cohort of 1,248 patients with Gleason 7 tumors. World J Urol 2 11 ; 5 :
5 GLEASON 7 PROSTATE CANCER 7 D Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A, Kantoff PW. 6-Month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA 24 ; 292 : Stone NN, Stock RG. Prostate brachytherapy: treatment strategies. J Urol 1999 ; 162 : Stock RG, Stone NN, Wesson MF, DeWyngaert JK. A modified technique allowing interactive ultrasound-guided three-dimensional transperineal prostate implantation. Int J Radiat Oncol Biol Phys 1995 ; 32 : Stock RG, Stone NN, Cesaretti JA, Rosenstein BS. Biologically effective dose values for prostate brachytherapy: effects on PSA failure and posttreatment biopsy results. Int J Radiat Oncol Biol Phys 26 ; 64 : Roach M 3rd, Hanks G, Thames H et al. D efining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 26 ; 65 : Norusis MJ. SPSS 1 Guide to Data Analysis. Upper Saddle River : Prentice Hall, 2 13 Stark JR, Perner S, Stampfer MJ et al. Gleason score and lethal prostate cancer: does = 4 + 3? J Clin Oncol 29 ; 27 : Merrick GS, Galbreath RW, Butler WM et al. Primary Gleason pattern does not impact survival after permanent interstitial brachytherapy for Gleason score 7 prostate cancer. Cancer 27 ; 11 : Brimo F, Partin AW, Epstein JI. Tumor grade at margins of resection in radical prostatectomy specimens is an independent predictor of prognosis. Urology 21 ; 76 : Swanson GP, Hussey MA, Tangen CM et al. Predominant treatment failure in postprostatectomy patients is local: analysis of patterns of treatment failure in SWOG J Clin Oncol 27 ; 25 : Thompson IM, Tangen CM, Paradelo J et al. Adjuvant radiotherapy for pathological T3NM prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol 29 ; 181 : Stone NN, Stone MM, Rosenstein BS, Unger P, Stock RG. Influence of pretreatment and treatment factors on intermediate to long-term outcome after prostate brachytherapy. J Urol 211 ; 185 : Ho AY, Burri RJ, Cesaretti JA, Stone NN, Stock RG. Radiation dose predicts for biochemical control in intermediaterisk prostate cancer patients treated with low-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys 29 ; 75 : Correspondence: Richard G. Stock, Director of Prostate Programs, Department of Radiation Oncology Mount Sinai School of Medicine, New York, NY 129, USA. Richard.stock@mountsinai.org Abbreviations : NCCN, National Comprehensive Cancer Network ; pd-13, palladium-13 ; I-125, iodine-125 ; FFBF, freedom from biochemical failure ; EBRT, external beam radiation therapy ; BED, biologically effective dose
failure (FBF) rates were calculated using the Phoenix definition.
. JOURNAL COMPILATION 2009 BJU INTERNATIONAL Urological Oncology GLEASON SCORES 8 10 PROSTATE CANCER TREATED WITH TRIMODAL THERAPY STOCK et al. BJUI BJU INTERNATIONAL Outcomes for patients with high-grade
More informationNIH Public Access Author Manuscript World J Urol. Author manuscript; available in PMC 2012 February 1.
NIH Public Access Author Manuscript Published in final edited form as: World J Urol. 2011 February ; 29(1): 11 14. doi:10.1007/s00345-010-0625-4. Significance of preoperative PSA velocity in men with low
More informationPercent Gleason pattern 4 in stratifying the prognosis of patients with intermediate-risk prostate cancer
Review Article Percent Gleason pattern 4 in stratifying the prognosis of patients with intermediate-risk prostate cancer Meenal Sharma 1, Hiroshi Miyamoto 1,2,3 1 Department of Pathology and Laboratory
More informationPost Radical Prostatectomy Radiation in Intermediate and High Risk Group Prostate Cancer Patients - A Historical Series
Post Radical Prostatectomy Radiation in Intermediate and High Risk Group Prostate Cancer Patients - A Historical Series E. Z. Neulander 1, Z. Wajsman 2 1 Department of Urology, Soroka UMC, Ben Gurion University,
More informationJure Murgic 1, Matthew H Stenmark 1, Schuyler Halverson 1, Kevin Blas 1, Felix Y Feng 1,2 and Daniel A Hamstra 1,3*
Murgic et al. Radiation Oncology 2012, 7:127 RESEARCH Open Access The role of the maximum involvement of biopsy core in predicting outcome for patients treated with dose-escalated radiation therapy for
More informationPredictive factors of late biochemical recurrence after radical prostatectomy
JJCO Japanese Journal of Clinical Oncology Japanese Journal of Clinical Oncology, 2017, 47(3) 233 238 doi: 10.1093/jjco/hyw181 Advance Access Publication Date: 9 December 2016 Original Article Original
More information2015 myresearch Science Internship Program: Applied Medicine. Civic Education Office of Government and Community Relations
2015 myresearch Science Internship Program: Applied Medicine Civic Education Office of Government and Community Relations Harguneet Singh Science Internship Program: Applied Medicine Comparisons of Outcomes
More informationProposed prognostic scoring system evaluating risk factors for biochemical recurrence of prostate cancer after salvage radiation therapy
Proposed prognostic scoring system evaluating risk factors for biochemical recurrence of prostate cancer after salvage radiation therapy Richard J. Lee, Katherine S. Tzou, Michael G. Heckman*, Corey J.
More informationconcordance indices were calculated for the entire model and subsequently for each risk group.
; 2010 Urological Oncology ACCURACY OF KATTAN NOMOGRAM KORETS ET AL. BJUI Accuracy of the Kattan nomogram across prostate cancer risk-groups Ruslan Korets, Piruz Motamedinia, Olga Yeshchina, Manisha Desai
More informationSalvage prostatectomy for post-radiation adenocarcinoma with treatment effect: Pathological and oncological outcomes
ORIGINAL RESEARCH Salvage prostatectomy for post-radiation adenocarcinoma with treatment effect: Pathological and oncological outcomes Michael J. Metcalfe, MD ; Patricia Troncoso, MD 2 ; Charles C. Guo,
More informationA comparative study of radical prostatectomy and permanent seed brachytherapy for low- and intermediate-risk prostate cancer
ORIGINAL RESEARCH A comparative study of radical prostatectomy and permanent seed brachytherapy for low- and intermediate-risk prostate cancer Daniel Taussky, MD; 1 Véronique Ouellet, MD; 2 Guila Delouya,
More informationOutcomes Following Negative Prostate Biopsy for Patients with Persistent Disease after Radiotherapy for Prostate Cancer
Clinical Urology Post-radiotherapy Prostate Biopsy for Recurrent Disease International Braz J Urol Vol. 36 (1): 44-48, January - February, 2010 doi: 10.1590/S1677-55382010000100007 Outcomes Following Negative
More informationEvaluation of prognostic factors after radical prostatectomy in pt3b prostate cancer patients in Japanese population
Japanese Journal of Clinical Oncology, 2015, 45(8) 780 784 doi: 10.1093/jjco/hyv077 Advance Access Publication Date: 15 May 2015 Original Article Original Article Evaluation of prognostic factors after
More informationSupported by M. D. Anderson Cancer Center physician investigator funds. We thank Gerald E. Hanks, MD, for help and guidance with this project.
1496 Biochemical and Clinical Significance of the Posttreatment Prostate-Specific Antigen Bounce for Prostate Cancer Patients Treated With External Beam Radiation Therapy Alone A Multiinstitutional Pooled
More informationHeterogeneity in high-risk prostate cancer treated with high-dose radiation therapy and androgen deprivation therapy
Cagney et al. BMC Urology (2017) 17:60 DOI 10.1186/s12894-017-0250-2 RESEARCH ARTICLE Heterogeneity in high-risk prostate cancer treated with high-dose radiation therapy and androgen deprivation therapy
More informationOriginal Article. Cancer September 15,
Gleason Pattern 5 Is the Strongest Pathologic Predictor of Recurrence, Metastasis, and Prostate Cancer-Specific Death in Patients Receiving Salvage Radiation Therapy Following Radical Prostatectomy William
More informationPredictors of time to biochemical recurrence in a radical prostatectomy cohort within the PSA-era
ORIGINAL RESEARCH Predictors of time to biochemical recurrence in a radical prostatectomy cohort within the PSA-era Ahva Shahabi, MPH, PhD; 1* Raj Satkunasivam, MD; 2* Inderbir S. Gill, MD; 2 Gary Lieskovsky,
More informationPreoperative Gleason score, percent of positive prostate biopsies and PSA in predicting biochemical recurrence after radical prostatectomy
JBUON 2013; 18(4): 954-960 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Gleason score, percent of positive prostate and PSA in predicting biochemical
More informationOverview of Radiotherapy for Clinically Localized Prostate Cancer
Session 16A Invited lectures: Prostate - H&N. Overview of Radiotherapy for Clinically Localized Prostate Cancer Mack Roach III, MD Department of Radiation Oncology UCSF Helen Diller Family Comprehensive
More informationOutcomes of Radical Prostatectomy in Thai Men with Prostate Cancer
Original Article Outcomes of Radical Prostatectomy in Thai Men with Prostate Cancer Sunai Leewansangtong, Suchai Soontrapa, Chaiyong Nualyong, Sittiporn Srinualnad, Tawatchai Taweemonkongsap and Teerapon
More informationDo all men with pathological Gleason score 8 10 prostate cancer have poor outcomes? Results from the SEARCH database
Do all men with pathological Gleason score 8 10 prostate cancer have poor outcomes? Results from the SEARCH database Sean Fischer*, Daniel Lin, Ross M. Simon*, Lauren E. Howard, William J. Aronson **,
More informationRadiation Therapy for Prostate Cancer. Resident Dept of Urology General Surgery Grand Round November 24, 2008
Radiation Therapy for Prostate Cancer Amy Hou,, MD Resident Dept of Urology General Surgery Grand Round November 24, 2008 External Beam Radiation Advances Improving Therapy Generation of linear accelerators
More informationProstate Cancer: 2010 Guidelines Update
Prostate Cancer: 2010 Guidelines Update James L. Mohler, MD Chair, NCCN Prostate Cancer Panel Associate Director for Translational Research, Professor and Chair, Department of Urology, Roswell Park Cancer
More informationResearch Article Implant R100 Predicts Rectal Bleeding in Prostate Cancer Patients Treated with IG-IMRT to 45 Gy and Pd-103 Implant
Radiotherapy, Article ID 130652, 6 pages http://dx.doi.org/10.1155/2014/130652 Research Article Implant R100 Predicts Rectal Bleeding in Prostate Cancer Patients Treated with IG-IMRT to 45 Gy and Pd-103
More informationUC San Francisco UC San Francisco Previously Published Works
UC San Francisco UC San Francisco Previously Published Works Title The quantitative Gleason score improves prostate cancer risk assessment Permalink https://escholarship.org/uc/item/9wq7g6k5 Journal Cancer,
More informationDebate: Whole pelvic RT for high risk prostate cancer??
Debate: Whole pelvic RT for high risk prostate cancer?? WPRT well, at least it ll get the job done.or will it? Andrew K. Lee, MD, MPH Associate Professor Department of Radiation Oncology Using T-stage,
More information1. INTRODUCTION. ARC Journal of Urology Volume 1, Issue 1, 2016, PP 1-7 Abstract:
ARC Journal of Urology Volume 1, Issue 1, 2016, PP 1-7 www.arcjournals.org Does the Number of Lymph Nodes Removed During Radical Prostatectomy Impact Risk of Biochemical Recurrence in Patients With Isolated
More informationCONTEMPORARY UPDATE OF PROSTATE CANCER STAGING NOMOGRAMS (PARTIN TABLES) FOR THE NEW MILLENNIUM
RAPID COMMUNICATION CME ARTICLE CONTEMPORARY UPDATE OF PROSTATE CANCER STAGING NOMOGRAMS (PARTIN TABLES) FOR THE NEW MILLENNIUM ALAN W. PARTIN, LESLIE A. MANGOLD, DANA M. LAMM, PATRICK C. WALSH, JONATHAN
More informationBest Papers. F. Fusco
Best Papers UROLOGY F. Fusco Best papers - 2015 RP/RT Oncological outcomes RP/RT IN ct3 Utilization trends RP/RT Complications Evolving role of elnd /Salvage LND This cohort reflects the current clinical
More informationChristine M. Fisher, MD
Prostate biopsy upgrading and its implications on treatment modality and outcomes in men treated with radical prostatectomy or permanent seed implantation at UT M.D. Anderson Cancer Center, 2000-2001 By
More informationEarly outcomes of active surveillance for localized prostate cancer
Original Article ACTIVE SURVEILLANCE FOR LOCALIZED PROSTATE CANCER HARDIE et al. Early outcomes of active surveillance for localized prostate cancer CLAIRE HARDIE, CHRIS PARKER, ANDREW NORMAN*, ROS EELES,
More informationTanaka et al. BMC Cancer (2017) 17:573 DOI /s
Tanaka et al. BMC Cancer (2017) 17:573 DOI 10.1186/s12885-017-3565-1 RESEARCH ARTICLE Comparison of PSA value at last follow-up of patients who underwent low-dose rate brachytherapy and intensity-modulated
More informationFive-year outcomes after iodine-125 seed brachytherapy for low-risk prostate cancer at three cancer centres in the UK
Five-year outcomes after iodine-125 seed brachytherapy for low-risk prostate cancer at three cancer centres in the UK Peter D. Dickinson*, Jahangeer Malik, Paula Mandall*, Ric Swindell*, David Bottomley,
More informationPrognostic value of the Gleason score in prostate cancer
BJU International (22), 89, 538 542 Prognostic value of the Gleason score in prostate cancer L. EGEVAD, T. GRANFORS*, L. KARLBERG*, A. BERGH and P. STATTIN Department of Pathology and Cytology, Karolinska
More informationVol. 36, pp , 2008 T1-3N0M0 : T1-3. prostate-specific antigen PSA. 68 Gy National Institutes of Health 10
25 Vol. 36, pp. 25 32, 2008 T1-3N0M0 : 20 2 18 T1-3 N0M0 1990 2006 16 113 59.4-70 Gy 68 Gy 24 prostate-specific antigen PSA 1.2 17.2 6.5 5 91 95 5 100 93 p 0.04 T3 PSA60 ng ml 68 Gy p 0.0008 0.03 0.04
More informationImplementation Date: July 2014 Clinical Operations
National Imaging Associates, Inc. Clinical guideline PROSTATE CANCER Original Date: March 2011 Page 1 of 10 Radiation Oncology Last Review Date: March 2014 Guideline Number: NIA_CG_124 Last Revised Date:
More informationOncologic Outcomes of Patients With Gleason Score 7 and Tertiary Gleason Pattern 5 After Radical Prostatectomy
www.kjurology.org http://dx.doi.org/10.4111/kju.2013.54.9.587 Urological Oncology Oncologic Outcomes of Patients With Gleason Score 7 and Tertiary Gleason Pattern 5 After Radical Prostatectomy Yi-Hsueh
More informationRadical Prostatectomy versus Intensity Modulated Radiation Therapy in the Management of Localized Prostate Cancer
Yale University EliScholar A Digital Platform for Scholarly Publishing at Yale Yale Medicine Thesis Digital Library School of Medicine 10-19-2009 Radical Prostatectomy versus Intensity Modulated Radiation
More informationRadical prostatectomy as radical cure of prostate cancer in a high risk group: A single-institution experience
MOLECULAR AND CLINICAL ONCOLOGY 1: 337-342, 2013 Radical prostatectomy as radical cure of prostate cancer in a high risk group: A single-institution experience NOBUKI FURUBAYASHI 1, MOTONOBU NAKAMURA 1,
More informationProstate MRI: Who needs it?
Prostate MRI: Who needs it? Fergus Coakley MD, Professor of Radiology and Urology, Vice Chair for Clinical Services, Chief of Abdominal Imaging, UCSF Abdominal Imaging Magnetic Resonance Science Center
More informationSupplemental Information
Supplemental Information Prediction of Prostate Cancer Recurrence using Quantitative Phase Imaging Shamira Sridharan 1, Virgilia Macias 2, Krishnarao Tangella 3, André Kajdacsy-Balla 2 and Gabriel Popescu
More informationTreatment Failure After Primary and Salvage Therapy for Prostate Cancer
307 Treatment Failure After Primary and Salvage Therapy for Prostate Cancer Likelihood, Patterns of Care, and Outcomes Piyush K. Agarwal, MD 1 Natalia Sadetsky, MD, MPH 2 Badrinath R. Konety, MD, MBA 2
More informationLong-term Oncological Outcome and Risk Stratification in Men with High-risk Prostate Cancer Treated with Radical Prostatectomy
Jpn J Clin Oncol 2012;42(6)541 547 doi:10.1093/jjco/hys043 Advance Access Publication 28 March 2012 Long-term Oncological Outcome and Risk Stratification in Men with High-risk Prostate Cancer Treated with
More informationClinical Case Conference
Clinical Case Conference Intermediate-risk prostate cancer 08/06/2014 Long Pham Clinical Case 64 yo man was found to have elevated PSA of 8.65. TRUS-biopies were negative. Surveillance PSA was 7.2 in 3
More informationCLINICAL TRIALS Open clinical uro-oncology trials in Canada George Rodrigues, MD, Eric Winquist, MD
Open clinical uro-oncology trials in Canada George Rodrigues, MD, Eric Winquist, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer AN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE II
More informationPSA bouncing after brachytherapy HDR and external beam radiation therapy: a study of 121 patients with minimum 5-years follow-up
Original article Original articles PSA bouncing after brachytherapy HDR and external beam radiation therapy: a study of 121 patients with minimum 5-years follow-up Roman Makarewicz, MD, PhD, Prof., Andrzej
More informationJournal of American Science 2018;14(1)
Salvage Radiotherapy Following Radical Prostatectomy: The Proper Timing and Clinical Benefits Mohamed F. Sheta 1, MD, Esam A. Abo-Zena 1, MD and Mohamed H. Radwan 2, MD 1 Department of Clinical Oncology,
More informationBiochemical progression-free survival in localized prostate cancer patients treated with definitive external beam radiotherapy
Electronic Physician (ISSN: 2008-5842) http://www.ephysician.ir October 2015, Volume: 7, Issue: 6, Pages: 1330-1335, DOI: 10.14661/1330 Biochemical progression-free survival in localized prostate cancer
More informationGUIDELINES ON PROSTATE CANCER
10 G. Aus (chairman), C. Abbou, M. Bolla, A. Heidenreich, H-P. Schmid, H. van Poppel, J. Wolff, F. Zattoni Eur Urol 2001;40:97-101 Introduction Cancer of the prostate is now recognized as one of the principal
More informationCase Discussions: Prostate Cancer
Case Discussions: Prostate Cancer Andrew J. Stephenson, MD FRCSC FACS Chief, Urologic Oncology Glickman Urological and Kidney Institute Cleveland Clinic Elevated PSA 1 54 yo, healthy male, family Hx of
More informationWhen PSA fails. Urology Grand Rounds Alexandra Perks. Rising PSA after Radical Prostatectomy
When PSA fails Urology Grand Rounds Alexandra Perks Rising PSA after Radical Prostatectomy Issues Natural History Local vs Metastatic Treatment options 1 10 000 men / year in Canada 4000 RRP 15-year PSA
More informationthree after the most recent release in These modifications were based primarily on data from clinical, not pathological, staging [1].
. 2010 BJU INTERNATIONAL Urological Oncology PATHOLOGICAL T2 SUB-DIVISIONS AS A PROGNOSTIC FACTOR IN PROSTATE CANCER CASO ET AL. BJUI BJU INTERNATIONAL Pathological T2 sub-divisions as a prognostic factor
More informationInformation Content of Five Nomograms for Outcomes in Prostate Cancer
Anatomic Pathology / NOMOGRAMS IN PROSTATE CANCER Information Content of Five Nomograms for Outcomes in Prostate Cancer Tarek A. Bismar, MD, 1 Peter Humphrey, MD, 2 and Robin T. Vollmer, MD 3 Key Words:
More informationClinical Study Oncologic Outcomes of Surgery in T3 Prostate Cancer: Experience of a Single Tertiary Center
Advances in Urology Volume 22, Article ID 64263, 8 pages doi:.55/22/64263 Clinical Study Oncologic Outcomes of Surgery in T3 Prostate Cancer: Experience of a Single Tertiary Center D. Milonas, G. Smailyte,
More informationestimating risk of BCR and risk of aggressive recurrence after RP was assessed using the concordance index, c.
. JOURNAL COMPILATION 2008 BJU INTERNATIONAL Urological Oncology PREDICTION OF AGGRESSIVE RECURRENCE AFTER RP SCHROECK et al. BJUI BJU INTERNATIONAL Do nomograms predict aggressive recurrence after radical
More informationClinical and biochemical outcomes of men undergoing radical prostatectomy or radiation therapy for localized prostate cancer
Original Article Radiat Oncol J 205;33():2-28 http://dx.doi.org/0.3857/roj.205.33..2 pissn 2234-900 eissn 2234-356 Clinical and biochemical outcomes of men undergoing radical prostatectomy or radiation
More informationUnderstanding the risk of recurrence after primary treatment for prostate cancer. Aditya Bagrodia, MD
Understanding the risk of recurrence after primary treatment for prostate cancer Aditya Bagrodia, MD Aditya.bagrodia@utsouthwestern.edu 423-967-5848 Outline and objectives Prostate cancer demographics
More informationThe Phoenix Definition of Biochemical Failure Predicts for Overall Survival in Patients With Prostate Cancer
55 The Phoenix Definition of Biochemical Failure Predicts for Overall Survival in Patients With Prostate Cancer Matthew C. Abramowitz, MD 1 Tiaynu Li, MA 2 Mark K. Buyyounouski, MD 1 Eric Ross, PhD 2 Robert
More informationWhen radical prostatectomy is not enough: The evolving role of postoperative
When radical prostatectomy is not enough: The evolving role of postoperative radiation therapy Dr Tom Pickles Clinical Associate Professor, UBC. Chair, Provincial Genito-Urinary Tumour Group BC Cancer
More informationOver the last decade, prostate brachytherapy a radiation treatment
135 Modern Prostate Brachytherapy Prostate Specific Antigen Results in 219 Patients with up to 12 Years of Observed Follow-Up Haakon Ragde, M.D. 1 Leroy J. Korb, M.D. 1 Abdel-Aziz Elgamal, M.D. 2 Gordon
More informationJAMA. 1998;280:
Original Contributions Biochemical Outcome After Radical Prostatectomy, Radiation Therapy, or Interstitial for Clinically Localized Prostate Cancer Anthony V. D Amico, MD, PhD; Richard Whittington, MD;
More informationExternal validation of the Briganti nomogram to estimate the probability of specimen-confined disease in patients with high-risk prostate cancer
External validation of the Briganti nomogram to estimate the probability of specimen-confined disease in patients with high-risk prostate cancer Mathieu Roumiguié, Jean-Baptiste Beauval, Thomas Filleron*,
More informationDepartment of Urology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara , Japan 2
Advances in Urology Volume 2012, Article ID 204215, 7 pages doi:10.1155/2012/204215 Research Article Calculated Tumor Volume Is an Independent Predictor of Biochemical Recurrence in Patients Who Underwent
More informationOpen clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD
CLINICAL TRIALS Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer A PHASE II PROTOCOL FOR PATIENTS
More informationRisk Factors for Clinical Metastasis in Men Undergoing Radical Prostatectomy and Immediate Adjuvant Androgen Deprivation Therapy
RESEARCH ARTICLE Risk Factors for Clinical Metastasis in Men Undergoing Radical Prostatectomy and Immediate Adjuvant Androgen Deprivation Therapy Satoru Taguchi, Hiroshi Fukuhara*, Shigenori Kakutani,
More informationThree-dimensional computed tomography-guided monotherapeutic pararectal brachytherapy of prostate cancer with seminal vesicle invasion
Radiotherapy and Oncology 60 (2001) 31±35 www.elsevier.com/locate/radonline Three-dimensional computed tomography-guided monotherapeutic pararectal brachytherapy of prostate cancer with seminal vesicle
More informationOpen clinical uro-oncology trials in Canada
Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer A PHASE II PROTOCOL FOR PATIENTS WITH STAGE T1
More informationShort ( 1 mm) positive surgical margin and risk of biochemical recurrence after radical prostatectomy
Short ( 1 mm) positive surgical margin and risk of biochemical recurrence after radical prostatectomy Sergey Shikanov, Pablo Marchetti, Vikas Desai, Aria Razmaria, Tatjana Antic, Hikmat Al-Ahmadie*, Gregory
More informationORIGINAL ARTICLE. Ja Hyeon Ku 1, Kyung Chul Moon 2, Sung Yong Cho 1, Cheol Kwak 1 and Hyeon Hoe Kim 1
(2011) 13, 248 253 ß 2011 AJA, SIMM & SJTU. All rights reserved 1008-682X/11 $32.00 www.nature.com/aja ORIGINAL ARTICLE Serum prostate-specific antigen value adjusted for non-cancerous prostate tissue
More informationTime to failure after definitive therapy for prostate cancer: implications for importance of aggressive local treatment
Original paper Clinical Investigations Time to failure after definitive therapy for prostate cancer: implications for importance of aggressive local treatment Al V. Taira, MD 1, Gregory S. Merrick, MD
More informationRadiation Therapy After Radical Prostatectomy
Articles ISSN 1537-744X; DOI 10.1100/tsw.2004.93 Radiation Therapy After Radical Ali M. Ziada, M.D. and E. David Crawford, M.D. Division of Urology, University of Colorado, Denver, Colorado E-mails: aziada@mednet3.camed.eun.eg
More informationBIOCHEMICAL RECURRENCE POST RADICAL PROSTATECTOMY
BIOCHEMICAL RECURRENCE POST RADICAL PROSTATECTOMY AZHAN BIN YUSOFF AZHAN BIN YUSOFF 2013 SCENARIO A 66 year old man underwent Robotic Radical Prostatectomy for a T1c Gleason 4+4, PSA 15 ng/ml prostate
More informationCorrespondence should be addressed to Taha Numan Yıkılmaz;
Advances in Medicine Volume 2016, Article ID 8639041, 5 pages http://dx.doi.org/10.1155/2016/8639041 Research Article External Validation of the Cancer of the Prostate Risk Assessment Postsurgical Score
More informationComparison between preoperative and real-time intraoperative planning 125 I permanent prostate brachytherapy: long-term clinical biochemical outcome
Matzkin et al. Radiation Oncology 2013, 8:288 RESEARCH Open Access Comparison between preoperative and real-time intraoperative planning 125 I permanent prostate brachytherapy: long-term clinical biochemical
More informationPermanent Prostate Brachytherapy Post Procedure Evaluation
Permanent Prostate Brachytherapy Post Procedure Evaluation William S. Bice, Jr., Ph.D. UTHSCSA, San Antonio, Texas IMPS, San Antonio, Texas Texas Cancer Clinic, San Antonio, Texas Implant Evaluation for
More informationAccepted for publication 3 January 2005
Original Article RACIAL DIFFERENCES IN PSA DOUBLING TIME AND RECURRENCE TEWARI et al. In a multi-institutional study authors from the USA and Austria attempt to determine if there are differences in several
More informationSince the beginning of the prostate-specific antigen (PSA) era in the. Characteristics of Insignificant Clinical T1c Prostate Tumors
2001 Characteristics of Insignificant Clinical T1c Prostate Tumors A Contemporary Analysis Patrick J. Bastian, M.D. 1 Leslie A. Mangold, B.A., M.S. 1 Jonathan I. Epstein, M.D. 2 Alan W. Partin, M.D., Ph.D.
More informationAccuracy of post-radiotherapy biopsy before salvage radical prostatectomy
Accuracy of post-radiotherapy biopsy before salvage radical prostatectomy Joshua J. Meeks, Marc Walker*, Melanie Bernstein, Matthew Kent and James A. Eastham Urology Service, Department of Surgery and
More informationLong-Term Risk of Clinical Progression After Biochemical Recurrence Following Radical Prostatectomy: The Impact of Time from Surgery to Recurrence
EUROPEAN UROLOGY 59 (2011) 893 899 available at www.sciencedirect.com journal homepage: www.europeanurology.com Platinum Priority Prostate Cancer Editorial by Bertrand D. Guillonneau and Karim Fizazi on
More informationQ&A. Overview. Collecting Cancer Data: Prostate. Collecting Cancer Data: Prostate 5/5/2011. NAACCR Webinar Series 1
Collecting Cancer Data: Prostate NAACCR 2010-2011 Webinar Series May 5, 2011 Q&A Please submit all questions concerning webinar content through the Q&A panel Overview NAACCR 2010-2011 Webinar Series 1
More informationThe use of hormonal therapy with radiotherapy for prostate cancer: analysis of prospective randomised trials
British Journal of Cancer (2004) 90, 950 954 All rights reserved 0007 0920/04 $25.00 www.bjcancer.com Minireview The use of hormonal therapy with radiotherapy for prostate cancer: analysis of prospective
More information2/14/09. Why Discuss this topic? Managing Local Recurrences after Radiation Failure. PROSTATE CANCER Second Treatment
Why Discuss this topic? Mack Roach III, MD Professor and Chair Radiation Oncology UCSF Managing Local Recurrences after Radiation Failure 1. ~15 to 75% of CaP pts recur after definitive RT. 2. Heterogeneous
More informationA NEURAL NETWORK PREDICTS PROGRESSION FOR MEN WITH GLEASON SCORE 3 4 VERSUS 4 3 TUMORS AFTER RADICAL PROSTATECTOMY
ADULT UROLOGY CME ARTICLE A NEURAL NETWORK PREDICTS PROGRESSION FOR MEN WITH GLEASON SCORE 3 4 VERSUS 4 3 TUMORS AFTER RADICAL PROSTATECTOMY MISOP HAN, PETER B. SNOW, JONATHAN I. EPSTEIN, THERESA Y. CHAN,
More informationMEDICAL POLICY. SUBJECT: BRACHYTHERAPY OR RADIOACTIVE SEED IMPLANTATION FOR PROSTATE CANCER POLICY NUMBER: CATEGORY: Technology Assessment
MEDICAL POLICY SUBJECT: BRACHYTHERAPY OR PAGE: 1 OF: 5 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases, medical policy
More informationImpact of the duration of hormonal therapy following radiotherapy for localized prostate cancer
ONCOLOGY LETTERS 10: 255-259, 2015 Impact of the duration of hormonal therapy following radiotherapy for localized prostate cancer MITSURU OKUBO, HIDETUGU NAKAYAMA, TOMOHIRO ITONAGA, YU TAJIMA, SACHIKA
More informationPrognostic Value of Surgical Margin Status for Biochemical Recurrence Following Radical Prostatectomy
Original Article Japanese Journal of Clinical Oncology Advance Access published January 17, 2008 Jpn J Clin Oncol doi:10.1093/jjco/hym135 Prognostic Value of Surgical Margin Status for Biochemical Recurrence
More informationProviding Treatment Information for Prostate Cancer Patients
Providing Treatment Information for Prostate Cancer Patients For all patients with localized disease on biopsy For all patients with adverse pathology after prostatectomy See what better looks like Contact
More informationPost Radical Prostatectomy Adjuvant Radiation in Patients with Seminal Vesicle Invasion - A Historical Series
Post Radical Prostatectomy Adjuvant Radiation in Patients with Seminal Vesicle Invasion - A Historical Series E. Z. Neulander 1, K. Rubinov 2, W. Mermershtain 2, Z. Wajsman 3 1 Department of Urology, Soroka
More informationORIGINAL INVESTIGATION. Impact of Biochemical Recurrence in Prostate Cancer Among US Veterans. having prostate cancer, assessment
ORIGINAL INVESTIGATION Impact of Biochemical Recurrence in Prostate Cancer Among US Veterans Edward M. Uchio, MD; Mihaela Aslan, PhD; Carolyn K. Wells, MPH; Juan Calderone, MD; John Concato, MD, MS, MPH
More informationRadiation Dose Escalation for Localized Prostate Cancer
Radiation Dose Escalation for Localized Prostate Cancer Intensity-Modulated Radiotherapy Versus Permanent Transperineal Brachytherapy William W. Wong, MD 1 ; Sujay A. Vora, MD 1 ; Steven E. Schild, MD
More informationPROVIDING TREATMENT INFORMATION FOR PROSTATE CANCER PATIENTS
PROVIDING TREATMENT INFORMATION FOR PROSTATE CANCER PATIENTS For patients with localized disease on biopsy* For patients with adverse pathology after prostatectomy Contact the GenomeDx Customer Support
More informationUC San Francisco UC San Francisco Previously Published Works
UC San Francisco UC San Francisco Previously Published Works Title Positive surgical margins in radical prostatectomy patients do not predict long-term oncological outcomes: Results from the Shared Equal
More informationNew Technologies for the Radiotherapy of Prostate Cancer
Prostate Cancer Meyer JL (ed): IMRT, IGRT, SBRT Advances in the Treatment Planning and Delivery of Radiotherapy. Front Radiat Ther Oncol. Basel, Karger, 27, vol. 4, pp 315 337 New Technologies for the
More informationHormone Therapy for Prostate Cancer: Guidelines versus Clinical Practice
european urology supplements 5 (2006) 362 368 available at www.sciencedirect.com journal homepage: www.europeanurology.com Hormone Therapy for Prostate Cancer: Guidelines versus Clinical Practice Antonio
More informationARRO-Case Postoperative Radiotherapy in Prostate Cancer
ARRO-Case Postoperative Radiotherapy in Prostate Cancer Kara Downs Romano, Daniel Trifiletti, Timothy Showalter Radiation Oncology University of Virginia Charlottesville, VA Case: HPI 64 year old man with
More informationPROSTATE BIOPSY: IS AGE IMPORTANT FOR DETERMINING THE PATHOLOGICAL FEATURES IN PROSTATE CANCER?
Clinical Urology International Braz J Urol Official Journal of the Brazilian Society of Urology AGE AND PATHOLOGY OF PROSTATE CA Vol. 31 (4): 331-337, July - August, 2005 PROSTATE BIOPSY: IS AGE IMPORTANT
More informationErectile Dysfunction (ED) after Radiotherapy (RT) for Prostate Cancer. William M. Mendenhall, MD
Erectile Dysfunction (ED) after Radiotherapy (RT) for Prostate Cancer William M. Mendenhall, MD Meta-Analysis of Probability of Maintaining Erectile Function after Treatment of Localized Cancer Treatment
More informationProstate Cancer: Is There Standard Treatment? Who has prostate cancer? In this article:
Focus on CME at l Université de Montréal Prostate Cancer: Is There Standard Treatment? Pierre I. Karakiewicz, MD, FRCSC; Paul Perrotte, MD, FRCSC; Fred Saad, MD, FRCSC In this article: 1. Risk factors
More informationACR Appropriateness Criteria Postradical Prostatectomy Irradiation in Prostate Cancer EVIDENCE TABLE
1. Bottke D, de Reijke TM, Bartkowiak D, Wiegel T. Salvage radiotherapy in with persisting/rising PSA after radical prostatectomy for prostate cancer. Eur J Cancer. 009;45 Suppl 1:148-157.. Valicenti RK,
More informationBJUI. Long-term overall survival and metastasis-free survival for men with prostate-specific antigenrecurrent
21 THE AUTHORS; 21 Urological Oncology DETERMINANTS OF SURVIVAL IN PSA-RECURRENT PROSTATE CANCER AFTER PROSTATECTOMY ANTONARAKIS ET AL. BJUI Long-term overall survival and metastasis-free survival for
More information